University Sues CVS Over $41 Million 340B Pricing Claims
Healthcare operators should review third-party pharmacy contracts for compliance with federal drug discount mandates.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you trust large pharmacy chains to fairly manage drug discount programs for local hospitals?
The University of Kentucky has filed a federal lawsuit alleging that CVS Health Corporation systematically overcharged the institution for medications, resulting in a loss of nearly $41 million. The litigation claims CVS failed to apply discounted 340B pharmacy program rates to hospital drug purchases between 2020 and 2025.
Why it matters
The case highlights critical compliance risks for healthcare operators relying on third-party pharmacy benefit managers to administer federal drug pricing programs. The university alleges that CVS diverted funds intended for discounted care for underserved patients toward its own financial growth.
The university reports an estimated financial loss of nearly $41 million, a figure it is now seeking to triple through RICO damages. These claims follow a period of alleged non-compliance spanning five years.
The players
University of Kentucky
A public research university operating healthcare facilities throughout the state.
CVS Health Corporation
A national healthcare company providing pharmacy services and pharmacy benefit management.
The details
The lawsuit alleges that CVS Health Corporation failed to apply mandated 340B discounts to medications purchased by the university, instead charging the institution full market prices and retaining the difference. According to the 66-paged filing, the university attempted to verify these transactions by requesting audit documents in November 2025, a request the company allegedly ignored prior to terminating their contract in April 2026.
Timeline
October 2020 to October 2025: Period of estimated financial loss for the university.
November 2025: University requested audit documents from CVS.
April 2026: CVS terminated its pharmacy contract with the university.
October 27, 2026: Lawsuit filed in federal court.
Market Landscape
This case follows a pattern established by 340B pharmacy program litigation in Michigan and Kansas. It marks a broader legal pushback against pharmacy benefit management practices regarding federal drug discount compliance.
Healthcare operators utilizing 340B pricing should audit their third-party pharmacy administrator invoices to ensure contracted discounts are being applied. Operators should also prepare for increased transparency requirements regarding drug pricing audit trails.
The takeaway
The case highlights the importance of maintaining rigorous audit rights in contracts with pharmacy benefit managers to prevent revenue leakage. Organizations should review their current third-party contracts for specific language regarding 340B compliance and audit access.
Further reading
For additional context on regulatory oversight in the sector, see Healthcare.
Source note: This article includes information reported by Lexington Herald Leader.
Live Poll
Do you trust large pharmacy chains to fairly manage drug discount programs for local hospitals?
